Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 2/20 | 0.59 |
| ▸ | CXCR4 | P61073 | 5/20 | 0.52 |
| ▸ | MC4R | P32245 | 3/20 | 0.52 |
| ▸ | CTSL | P07711 | 3/20 | 0.52 |
| ▸ | CTSS | P25774 | 3/20 | 0.52 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | CTSH | P09668 | 1/20 | 0.52 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.52 |
| ▸ | GLP1R | P43220 | 1/20 | 0.51 |
| ▸ | MC5R | P33032 | 2/20 | 0.51 |
| ▸ | MC3R | P41968 | 2/20 | 0.51 |
| ▸ | MC1R | Q01726 | 2/20 | 0.51 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.51 |
| ▸ | GNRHR | P30968 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30181849 | 0.96 | C5AR1 (0.59) | C5AR1CXCR4MC4RCTSLCTSS | |
| SCHEMBL29520158 | 0.96 | C5AR1 (0.61) | C5AR1CXCR4MC4RCTSLCTSS | |
| SCHEMBL29391110 | 0.95 | C5AR1 (0.64) | C5AR1CXCR4MC4RCTSLCTSS | |
| Acetic Acid SCHEMBL29811007 | 0.91 | C5AR1 (0.64) | C5AR1CXCR4MC4RCTSLCTSS | |
| SCHEMBL11033870 | 0.91 | C5AR1 (0.65) | C5AR1CXCR4MC4RCTSLCTSS | |
| SCHEMBL29390323 | 0.90 | ABCC2 (0.63) | C5AR1ABCC2GNRHR | |
| SCHEMBL29425255 | 0.90 | C5AR1 (0.68) | C5AR1CXCR4MC4RKISS1RGLP1R | |
| SCHEMBL29754493 | 0.89 | C5AR1 (0.68) | C5AR1CXCR4MC4RCTSLCTSS | |
| Acetic Acid SCHEMBL29810985 | 0.88 | C5AR1 (0.64) | C5AR1CXCR4MC4RCTSLCTSS | |
| SCHEMBL29391299 | 0.88 | C5AR1 (0.68) | C5AR1CXCR4MC4RCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| US-20260022117-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS INC (US) | 2026-01-22 | — | — | US | claimed |
| US-12485178-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | YALE UNIVERSITY (US) | 2025-12-02 | — | — | US | claimed |
| US-20250332274-A1 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | UNIV YALE (US) | 2025-10-30 | — | — | US | claimed |
| US-12364766-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | YALE UNIVERSITY (US) | 2025-07-22 | — | — | US | claimed |
| EP-4414369-A2 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | Arvinas, Inc. (US) | 2024-08-14 | — | — | EP | claimed |
| EP-3302572-B3 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2024-07-24 | — | — | EP | claimed |
| US-11672779-B2 | Modulators of GTPases and their use | UNM RAINFOREST INNOVATIONS (US) | 2023-06-13 | — | — | US | claimed |
| US-11512083-B2 | Compounds and methods for the enhanced degradation of targeted proteins | ARVINAS OPERATIONS, INC. (US) | 2022-11-29 | — | — | US | claimed |
| WO-2022169634-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-08-11 | — | — | WO | claimed |
| US-20220089570-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. | 2022-03-24 | — | — | US | claimed |
| EP-4342543-B1 | TERT-BUTYL 2-(4-PHENYL-6H-THIENO[3,2-F][1,2,4]TRIAZOLO[4,3-A] [1,4]DIAZEPIN-6-YL) ACETATE DERIVATIVES AS BROMODOMAIN BRD4 INHIBITORS FOR TREATING CANCER | HOFFMANN LA ROCHE (CH) | 2026-04-29 | — | — | EP | disclosed |
| US-12577249-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260053932-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260022117-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20220151924-A1 | MODULAR METAL–ORGANIC POLYHEDRA SUPERASSEMBLY COMPOSITIONS | UNM RAINFOREST INNOVATIONS | 2022-05-19 | — | — | US | disclosed |
| US-20220144809-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-05-12 | — | — | US | disclosed |
| EP-3236937-B1 | CONTROLLED-RELEASE FORMULATIONS | CAMURUS AB (SE) | 2022-05-04 | — | — | EP | disclosed |
| US-20220089570-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. | 2022-03-24 | — | — | US | disclosed |
| US-11241476-B2 | Mixtures and formulations comprising an alkyl ammonium EDTA salt | CAMURUS AB (SE) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11512083-B2 | Compounds and methods for the enhanced degradation of targeted proteins | VHL, MDM2, XIAP | C5AR1 4023/4885CXCR4 3746/4885MC4R 4143/4885 |
| US-12577249-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | EIF2AK4, GCN1, MAPKAPK2 | C5AR1 4281/4885CXCR4 1345/4885MC4R 3335/4885 |
| US-11241476-B2 | Mixtures and formulations comprising an alkyl ammonium EDTA salt | PHOSPHO1, LIPA, ABHD16A | C5AR1 825/4885CXCR4 3152/4885MC4R 3042/4885 |
| US-20260022117-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | VHL, ADRM1, MDM2 | C5AR1 4093/4885CXCR4 4119/4885MC4R 4272/4885 |
| US-20220144809-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND ASSOCIATED METHODS OF USE | AR, ADRM1, CRBN | C5AR1 2662/4885CXCR4 3989/4885MC4R 3103/4885 |
| US-12485178-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | ASGR1, LDLR, FCGR2A | C5AR1 55/4885CXCR4 1416/4885MC4R 3576/4885 |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | MDM2, UBR4, UBE3A | C5AR1 3763/4885CXCR4 4234/4885MC4R 3777/4885 |
| US-20250332274-A1 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | ASGR1, LDLR, FCGR3B | C5AR1 32/4885CXCR4 849/4885MC4R 2873/4885 |
| US-20220089570-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | CRBN, MDM2, UBE2N | C5AR1 3777/4885CXCR4 4005/4885MC4R 4129/4885 |
| US-11672779-B2 | Modulators of GTPases and their use | CDC42, RAC1, ROCK1 | C5AR1 1303/4885CXCR4 1192/4885MC4R 605/4885 |
| US-12364766-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | ASGR1, LDLR, FCGR3B | C5AR1 32/4885CXCR4 849/4885MC4R 2873/4885 |
| US-20260053932-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND ASSOCIATED METHODS OF USE | ADRM1, AR, CRBN | C5AR1 2347/4885CXCR4 3255/4885MC4R 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.